EGFR and neoplasm: In addition, Kooijmans et al. fused a nanobody encoding anti-epidermal growth factor receptor (anti-EGFR) as a targeting ligand for tumor cells with glycosylphosphatidylinositol (GPI) anchor signal peptides derived from decay-accelerating factor (DAF) [164].